MX2015005797A - Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica. - Google Patents
Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica.Info
- Publication number
- MX2015005797A MX2015005797A MX2015005797A MX2015005797A MX2015005797A MX 2015005797 A MX2015005797 A MX 2015005797A MX 2015005797 A MX2015005797 A MX 2015005797A MX 2015005797 A MX2015005797 A MX 2015005797A MX 2015005797 A MX2015005797 A MX 2015005797A
- Authority
- MX
- Mexico
- Prior art keywords
- coli
- production
- recombinant vaccine
- enzymatic conjugation
- glycoconjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
En la presente, se proporcionan células procarióticas eficientes para producir glucoconjugados in vivo, así como los métodos para generar estas células, y los métodos para utilizar estas células para producir glucoconjugados. También se incluyen composiciones de los glucoconjugados mencionados así como sus diferentes usos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| PCT/EP2013/073266 WO2014072405A1 (en) | 2012-11-07 | 2013-11-07 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005797A true MX2015005797A (es) | 2016-03-09 |
| MX366912B MX366912B (es) | 2019-07-30 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005797A MX366912B (es) | 2012-11-07 | 2013-11-07 | Producción de vacuna recombinante en e. coli mediante conjugación enzimática. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (es) |
| EP (3) | EP3508579B1 (es) |
| JP (2) | JP6412875B2 (es) |
| KR (1) | KR20150079964A (es) |
| CN (1) | CN105008539B (es) |
| AU (2) | AU2013343520B2 (es) |
| BR (1) | BR112015010283A8 (es) |
| CA (2) | CA3125293A1 (es) |
| EA (1) | EA201590705A1 (es) |
| ES (3) | ES2848774T3 (es) |
| IL (1) | IL238586A0 (es) |
| MX (1) | MX366912B (es) |
| SG (1) | SG11201503308XA (es) |
| TR (1) | TR201903066T4 (es) |
| WO (1) | WO2014072405A1 (es) |
| ZA (1) | ZA201503097B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010322454B2 (en) * | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| EP3055416B1 (en) | 2013-10-11 | 2020-01-22 | GlaxoSmithKline Biologicals S.A. | Methods of host cell modification |
| EP3110441B1 (en) | 2014-02-24 | 2024-04-03 | GlaxoSmithKline Biologicals S.A. | Novel polysaccharide and uses thereof |
| ES2805000T3 (es) * | 2014-04-17 | 2021-02-10 | Glaxosmithkline Biologicals Sa | Células huéspedes modificadas y usos de las mismas |
| AR104469A1 (es) | 2014-08-08 | 2017-07-26 | Glycovaxyn Ag | Células huésped modificadas para su uso en producción de bioconjugados |
| JP6764872B2 (ja) * | 2015-02-26 | 2020-10-07 | ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ | アシネトバクター（Ａｃｉｎｅｔｏｂａｃｔｅｒ）Ｏ−オリゴサッカリルトランスフェラーゼおよびその使用 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| US11235046B2 (en) | 2017-11-04 | 2022-02-01 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| EP3806881B1 (en) | 2018-06-16 | 2025-10-08 | Vaxnewmo Llc | Glycosylated comp pilin variants, methods of making and uses thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| AU2019404924B2 (en) | 2018-12-21 | 2025-09-18 | Vaxnewmo Llc | O-linked glycosylation recognition motifs |
| KR102574882B1 (ko) | 2019-03-18 | 2023-09-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법 |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN112369722B (zh) * | 2020-05-08 | 2023-03-17 | 湖北中烟工业有限责任公司 | 加热不燃烧装置和温度控制方法 |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| US20230346902A1 (en) * | 2020-06-18 | 2023-11-02 | Glaxosmithkline Biologicals Sa | Shigella-Tetravalent (Shigella4V) Bioconjugate |
| CA3185639A1 (en) | 2020-06-25 | 2021-12-30 | Glaxosmithkline Biologicals Sa | Vaccine |
| PH12023550020A1 (en) | 2020-09-17 | 2024-03-11 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and uses thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| EP4452308A1 (en) | 2021-12-22 | 2024-10-30 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804582A1 (en) * | 1994-05-16 | 1997-11-05 | The Uab Research Foundation | $i(STREPTOCOCCUS PNEUMONIAE) CAPSULAR POLYSACCHARIDE GENES AND FLANKING REGIONS |
| US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| PT1481057E (pt) | 2002-03-07 | 2006-05-31 | Eidgenoess Tech Hochschule | Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota |
| EP2311972B1 (en) | 2005-05-11 | 2015-01-21 | ETH Zurich | Recombinant N-glycosylated proteins from procaryotic cells |
| EP3427749A1 (en) | 2008-02-20 | 2019-01-16 | GlaxoSmithKline Biologicals SA | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| US9358302B2 (en) * | 2009-03-23 | 2016-06-07 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
| KR20120085240A (ko) | 2009-07-17 | 2012-07-31 | 오션 하베스트 테크놀로지 (캐나다) 아이엔씨. | 어류 사료에서 합성 첨가제를 대체하는 천연 및 지속 가능 해조류 배합 |
| SG185433A1 (en) | 2010-05-06 | 2012-12-28 | Glycovaxyn Ag | Capsular gram-positive bacteria bioconjugate vaccines |
| US20150267207A1 (en) * | 2012-10-12 | 2015-09-24 | Glycovaxyn Ag | Methods of host cell modification |
-
2013
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en not_active Ceased
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en not_active Ceased
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja not_active Expired - Fee Related
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh not_active Expired - Fee Related
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Withdrawn
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en not_active Ceased
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en not_active Expired - Fee Related
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX366912B (es) | Producción de vacuna recombinante en e. coli mediante conjugación enzimática. | |
| ZA201601534B (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
| SG10201900948PA (en) | Modified nucleotide linkers | |
| MX2013004353A (es) | Produccion recombinante de n-propanol e isopropanol. | |
| MY191370A (en) | Production of odd chain fatty acid derivatives in recombinant microbial cells | |
| EP4279579A3 (en) | Methods and compositions for natural killer cells | |
| MX2015008027A (es) | Proceso de glicoconjugacion. | |
| IN2014DN06104A (es) | ||
| MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
| MX351565B (es) | Colageno 7 y metodos relacionados. | |
| SG10201809452RA (en) | Cell culture compositions with antioxidants and methods for polypeptide production | |
| PH12014501556A1 (en) | Microorganism able to produce l-amino acid, and method for producing l-amino acid by using same | |
| MY182946A (en) | Production of organic acids by fermentation at low ph | |
| IN2012DN02210A (es) | ||
| IN2015DN03206A (es) | ||
| MY180645A (en) | Microbial production of fatty amines | |
| MX2011012623A (es) | Construcciones de casb7439. | |
| MX2015006986A (es) | Solucion de trombina y metodos de uso de esta. | |
| EP3456814A3 (en) | Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells | |
| IN2012DN02760A (es) | ||
| MX337070B (es) | Método para preparar un conjugado klh-egfrviii. | |
| MX2014007760A (es) | Bacterias con unidades transcripcionales reconstruidas y los usos de las mismas. | |
| MX2013005749A (es) | Composiciones y metodos para producir enterocinasa en levaduras. | |
| HK1210436A1 (en) | Novel cell compositions and methods | |
| WO2015117033A3 (en) | Methods of increasing protein production in mammalian cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. |
|
| FG | Grant or registration |